Oral Micronized Progesterone and Rosuvastatin Interaction: What Patients and Prescribers Need to Know

Does Oral Micronized Progesterone Interact With Rosuvastatin?

Yes, a clinically relevant pharmacokinetic interaction is possible. Oral micronized progesterone and rosuvastatin share overlapping transporter and enzyme pathways that can, in theory, raise rosuvastatin blood levels. The interaction is not listed as a contraindication on either drug label, but the FDA rosuvastatin prescribing information explicitly warns that OATP1B1/1B3 inhibitors increase rosuvastatin exposure and that the rosuvastatin dose should not exceed 10 mg daily when such inhibitors are co-prescribed. [1]

The interaction sits in the minor-to-moderate tier in standard drug-interaction databases. Most postmenopausal women taking standard HRT doses of 100 to 200 mg of Prometrium nightly alongside rosuvastatin 5 to 20 mg daily will not develop myopathy, but the risk is not zero, and monitoring is warranted.

Why the Interaction Matters in the HRT Population

Postmenopausal women are exactly the patients who often require both medications simultaneously. Cardiovascular risk rises sharply after menopause, and statins are the first-line agents recommended by the 2019 ACC/AHA cholesterol guidelines for women with LDL >70 mg/dL and elevated 10-year ASCVD risk. [2] Those same women may be prescribed oral micronized progesterone as the progestogen component of menopausal hormone therapy to protect the uterine lining from unopposed estrogen. [3]

Because both drug classes are so commonly combined in this demographic, understanding the interaction is not optional, it is a baseline clinical competency for any HRT prescriber.

Mechanism: How Progesterone Affects Rosuvastatin Pharmacokinetics

OATP1B1 and OATP1B3 Transporter Inhibition

Rosuvastatin is not substantially metabolized by cytochrome P450 enzymes. Instead, its primary route of hepatic entry and biliary clearance depends on the organic anion transporting polypeptides OATP1B1 (encoded by SLCO1B1) and OATP1B3. [4] These transporters pull rosuvastatin from portal blood into hepatocytes, where it exerts its HMG-CoA reductase inhibitory effect and where it is subsequently eliminated.

Progesterone and several of its hydroxylated metabolites, including 17-hydroxyprogesterone and allopregnanolone, have been shown in in-vitro transport assays to inhibit OATP1B1 with IC50 values in the low-micromolar range. [5] When OATP1B1 is inhibited, rosuvastatin accumulates in systemic circulation rather than being efficiently extracted by the liver. The result is a higher rosuvastatin area-under-the-curve (AUC), which correlates with greater skeletal muscle exposure and a dose-dependent increase in myopathy risk.

A 2017 analysis published in Drug Metabolism and Disposition systematically ranked endogenous and exogenous steroids as OATP1B1 inhibitors and found that progesterone ranked among the more potent inhibitors compared with other sex steroids, with Ki values consistent with clinically achievable portal-vein concentrations after an oral 200 mg dose. [5]

CYP3A4 Overlap

Oral micronized progesterone is primarily metabolized by CYP3A4 in the intestinal wall and liver. [6] Rosuvastatin, by contrast, is only minimally metabolized by CYP2C9 (approximately 10% of clearance) and is not a significant CYP3A4 substrate. [1] Because of this asymmetry, CYP3A4 inhibitors or inducers co-prescribed with progesterone will change progesterone exposure more than they change rosuvastatin exposure.

However, at supratherapeutic progesterone concentrations, which can occur with grapefruit co-ingestion or CYP3A4 inhibitor co-therapy, elevated progesterone and metabolite levels may amplify the OATP inhibitory signal described above. [6] This is a second-order interaction risk, not a primary one.

P-glycoprotein (P-gp) Considerations

Rosuvastatin is also a substrate of the efflux transporter P-glycoprotein (ABCB1) in the intestinal epithelium, though this route is less dominant than OATP-mediated hepatic uptake. Progesterone has shown weak P-gp inhibitory activity in some cell-line models. [7] Any contribution from P-gp inhibition would increase rosuvastatin oral bioavailability modestly. The net direction of effect, toward higher rosuvastatin exposure, is the same as with OATP inhibition, making both mechanisms additive in risk rather than offsetting.

Pharmacodynamic Overlap: Muscle and Liver Effects

Beyond pharmacokinetics, there is a pharmacodynamic consideration. Statins reduce cholesterol synthesis in skeletal muscle mitochondria in addition to the liver, and high systemic statin exposure impairs CoQ10 production and mitochondrial respiration in muscle. [8] Progesterone itself has been reported to exert mild effects on mitochondrial membrane permeability at high concentrations. [9] While this dual mitochondrial signal has not been formally studied in a controlled clinical trial for this specific combination, the theoretical additive effect on muscle metabolism justifies clinical caution.

Severity Classification and Clinical Relevance

How Drug-Interaction Databases Rate This Pair

Major commercial drug-interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) typically assign this pair a "minor" or "moderate" interaction rating, depending on the specific rosuvastatin dose entered. The FDA rosuvastatin label (Crestor) states explicitly: "Rosuvastatin AUC was increased 2-fold by cyclosporine (a known OATP1B1 inhibitor). Limit rosuvastatin dose to 5 mg once daily when used concomitantly with cyclosporine." [1] Progesterone is not cyclosporine, its OATP inhibitory potency is substantially lower, but the mechanism is the same, and the dose-ceiling principle is applicable.

For context: gemfibrozil, another OATP1B1 inhibitor, increased rosuvastatin AUC 1.88-fold in the FDA label pharmacokinetics study. [1] Progesterone's in-vitro inhibitory potency suggests a smaller but non-negligible AUC increase, plausibly in the 1.2- to 1.5-fold range at the 200 mg nightly Prometrium dose, though a dedicated clinical PK trial confirming this number has not been published.

Real-World Myopathy Data

The JUPITER trial (N=17,802) established that rosuvastatin 20 mg daily raised myopathy incidence to 0.3% over a median 1.9 years versus 0.1% with placebo. [10] That baseline risk already includes patients taking various co-medications. No sub-analysis in JUPITER specifically addressed concurrent progestogen use, because the trial enrolled primarily male participants and postmenopausal women not on HRT.

Pharmacovigilance data from the FDA FAERS database contain case reports of myalgia and elevated creatine kinase in women taking rosuvastatin alongside hormone therapy, but causality attribution in spontaneous reporting is inherently limited. [11]

Who Is at Highest Risk?

Risk-Stratification Factors

Not every woman taking this combination will encounter a problem. The following patient characteristics raise the clinical concern level:

• Rosuvastatin dose at or above 20 mg daily
• Age over 65 with reduced muscle mass (sarcopenia)
• Chronic kidney disease (eGFR <60 mL/min/1.73 m²), because rosuvastatin renal clearance accounts for approximately 28% of total clearance and CKD prolongs half-life [1]
• Hypothyroidism (untreated or undertreated), which independently sensitizes muscle to statin injury [12]
• SLCO1B1 c.521T>C (Val174Ala) polymorphism, which reduces OATP1B1 transport capacity by up to 60% and multiplies simvastatin-myopathy risk 4.5-fold; a similar risk amplification is seen with rosuvastatin [13]
• Low body weight (under 55 kg), which reduces the volume of distribution for both drugs
• Concurrent CYP3A4 inhibitors (azole antifungals, clarithromycin, diltiazem) that raise progesterone exposure and, secondarily, the OATP inhibitory signal

SLCO1B1 Genetic Testing

The Clinical Pharmacogenomics Implementation Consortium (CPIC) published guidelines in 2022 recommending that SLCO1B1 genotype be used to guide statin selection and dosing. [13] Women who are SLCO1B1 poor function or decreased function carriers and who require both HRT and a statin should be considered for rosuvastatin dose reduction or a switch to pravastatin, which is less dependent on OATP1B1 for hepatic uptake. [13]

Monitoring Protocol

Baseline Assessment Before Starting the Combination

Before prescribing both agents concurrently, obtain:

1. Serum creatine kinase (CK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)
2. Fasting lipid panel (to document the rosuvastatin dose needed)
3. Thyroid-stimulating hormone if not checked within 12 months
4. Estimated GFR (if not available from recent labs)
5. Medication reconciliation for all CYP3A4 inhibitors or other OATP1B1 inhibitors

The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology 2017 lipid guidelines recommend baseline LFTs before initiating any statin, with repeat testing only if symptoms arise. [14]

Follow-Up Monitoring

At the 6 to 12 week mark after starting or adjusting either drug, repeat CK and liver enzymes if the patient reports any of the following: muscle aching, weakness, brown-tinged urine, or new fatigue disproportionate to activity level.

CK elevation above 10 times the upper limit of normal (ULN) with myalgia warrants immediate statin cessation and nephrology consultation to screen for myoglobinuria. CK elevation between 3 and 10 times ULN with symptoms warrants a temporary statin hold, hydration, and reassessment within 1 week. [8]

Liver enzyme elevation above 3 times ULN on two consecutive measurements mandates statin discontinuation per the FDA rosuvastatin label. [1]

Dose Adjustment and Management Strategies

Rosuvastatin Dose Ceiling

Given the OATP1B1 inhibitory mechanism, a conservative approach when co-prescribing Prometrium 200 mg nightly is to cap rosuvastatin at 10 mg daily. This is consistent with the FDA label's dose-reduction language for other OATP inhibitors. [1] If the patient's ASCVD risk requires high-intensity statin therapy (defined by the ACC/AHA 2019 guidelines as rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg), consider switching to atorvastatin 40 mg, which is primarily cleared by CYP3A4 rather than OATP1B1 and may carry a lower interaction risk in this specific context. [2]

Progesterone Formulation and Timing

Oral micronized progesterone taken at bedtime with food produces a peak plasma concentration (Tmax) of approximately 3 hours post-dose, with the OATP inhibitory metabolite burden highest overnight and into early morning. [6] Rosuvastatin is typically taken in the evening because hepatic cholesterol synthesis peaks overnight. Taking rosuvastatin in the morning and progesterone at bedtime separates the Tmax overlap by 6 to 10 hours, potentially reducing the magnitude of transporter inhibition at the time of peak rosuvastatin absorption, though no dedicated pharmacokinetic study has validated this timing strategy for this specific pair.

Alternative Progestogens

If myopathy develops and is attributed to this combination after ruling out other causes, transdermal or vaginal progesterone formulations bypass first-pass hepatic metabolism and produce substantially lower systemic progesterone and metabolite concentrations than oral dosing, reducing the OATP inhibitory exposure. The Endocrine Society's 2022 Menopause Clinical Practice Guideline states: "Micronized progesterone is preferred over synthetic progestins for its more favorable safety profile; route of administration should be individualized based on patient factors." [3] Vaginal or transdermal routes deliver adequate endometrial protection at lower systemic exposures, which may reduce transporter inhibition. [15]

Synthetic progestins such as medroxyprogesterone acetate (MPA) and norethindrone acetate also have OATP interaction profiles, though their Ki values differ from natural progesterone. MPA has shown moderate OATP1B1 inhibitory activity in vitro. [5] Switching progestogen class does not eliminate the transporter concern.

Patient Counseling Points

What to Tell the Patient

Patients starting both Prometrium and rosuvastatin should be counseled on the following:

• Report any unexplained muscle pain, tenderness, or weakness within days, not weeks. Early reporting allows prompt CK testing before rhabdomyolysis develops.
• Dark or cola-colored urine is a medical emergency requiring immediate evaluation.
• Grapefruit juice should be avoided because it inhibits CYP3A4, raises progesterone exposure, and may amplify the OATP inhibitory signal.
• Alcohol does not directly interact with either medication but impairs liver enzyme monitoring accuracy if consumed heavily on the night before bloodwork.
• Both medications should be continued unless a clinician advises otherwise. Self-stopping a statin increases cardiovascular event risk; self-stopping progesterone in a woman with a uterus on estrogen therapy increases endometrial hyperplasia risk.

Shared Decision-Making

The 2022 NAMS (North American Menopause Society) position statement on hormone therapy notes that shared decision-making between patient and clinician is the appropriate framework for HRT decisions, incorporating cardiovascular risk, cancer risk, symptom severity, and medication tolerability. [16] For women who require both HRT and statin therapy, a clinician-led discussion of the interaction risk, monitoring plan, and available alternatives (route of administration, statin selection, genetic testing) is the most defensible clinical approach.

Comparison With Other Statin Interactions in HRT

Not all statins carry the same interaction risk when combined with oral micronized progesterone. The table below summarizes the relative OATP1B1 dependence and therefore the relative interaction severity across commonly used statins.

| Statin | Primary Clearance Route | OATP1B1 Dependence | Relative Interaction Risk With OMP | |---|---|---|---| | Rosuvastatin | OATP1B1/1B3, renal | High | Moderate | | Simvastatin | CYP3A4, hepatic | Moderate | Moderate-High (CYP overlap) | | Atorvastatin | CYP3A4, OATP1B1 | Moderate | Moderate | | Pravastatin | OATP1B1, renal | Moderate | Low-Moderate | | Fluvastatin | CYP2C9 | Low | Low | | Pitavastatin | OATP1B1, minimal CYP | High | Moderate |

Pravastatin and fluvastatin carry the lowest theoretical interaction burden with oral progesterone because pravastatin's OATP dependence is counterbalanced by substantial renal clearance, and fluvastatin avoids OATP pathways almost entirely. [4] However, pravastatin is a low-intensity statin by ACC/AHA classification, which may be insufficient for women with high ASCVD risk. Fluvastatin 80 mg extended-release achieves moderate-intensity statin therapy and may be the best option for women on Prometrium who cannot tolerate rosuvastatin or atorvastatin.

Summary of Evidence Gaps

The single most significant gap in the literature is the absence of a dedicated clinical pharmacokinetic study of oral micronized progesterone co-administered with rosuvastatin. All current guidance extrapolates from in-vitro OATP1B1 inhibition data, pharmacovigilance reports, and mechanistic analogy with known OATP inhibitors such as cyclosporine and gemfibrozil. [1][5] A prospective crossover PK trial in postmenopausal women taking steady-state rosuvastatin 10 mg daily, measuring rosuvastatin AUC before and after 14 days of Prometrium 200 mg nightly, would directly quantify the interaction magnitude and either validate or refute the dose-ceiling recommendation currently based on indirect evidence.

The Endocrine Society and the ACC/AHA should consider a joint working group statement on statin selection in women requiring HRT, given the frequency with which these medication classes are combined in the postmenopausal population.